Macro­Gen­ics ear­marks $580M for ADC tech; Do­mainex, non­prof­it team up on Parkin­son's pro­gram

Synaf­fix and Macro­Gen­ics have signed a deal to code­vel­op and com­mer­cial­ize a clin­i­cal plat­form for an­ti­body-drug con­ju­gates to fight can­cer.

Synaf­fix will li­cense out its Gly­co­Con­nect an­ti­body con­ju­ga­tion plat­form, po­lar spac­er tech­nol­o­gy and toxSYN link­er pay­loads. In re­turn, it will get $586 mil­lion in up­front and mile­stone pay­ments across the three pro­grams and is el­i­gi­ble for roy­al­ties on com­mer­cial sales.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN